Natco Pharma seeks CDSCO approval for Molnupiravir capsules

The drug can be used for the treatment of corona virus

Natco Pharma said it applied to the Central Drugs Standard Control Organisation (CDSCO) for approval of Phase-III clinical trial of Molnupiravir Capsules for the treatment of COVID-19 positive patients.


American pharma major Merck along with Ridgeback Biotherapeuticshasdeveloped Molnupiravir(MK-4482).

According to a press release from the Hyderabad-based drugmaker, pre-clinical data have shown that Molnupiravir has broad anti-influenza activity, including highly potent inhibition of SARS-CoV-2 replication.

“Patients treated with Molnupiravir achieved response within five days of therapy indicating that the duration of treatment with Molnupiravir is short, with the additional advantage of being an oral therapy,” it said.

NATCO is hoping that CDSCO would give emergency approval of this drug based on “compassionate use” for patients.

“Compassionate use” approval is given for investigational drugs so that a patient with an immediately life-threatening condition can gain access to the drug.

The company is ready to launch the product this month if approval is given.


Support us in our endeavor to bring you Advertisement free content.
Choose your options to donate or subscribe.


Related Articles

Leave a Reply

Back to top button